US20100179337A2 - Preparation of bile acids and intermediates thereof - Google Patents

Preparation of bile acids and intermediates thereof Download PDF

Info

Publication number
US20100179337A2
US20100179337A2 US12/153,446 US15344608A US2010179337A2 US 20100179337 A2 US20100179337 A2 US 20100179337A2 US 15344608 A US15344608 A US 15344608A US 2010179337 A2 US2010179337 A2 US 2010179337A2
Authority
US
United States
Prior art keywords
compound
formula
reacting
acid
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US12/153,446
Other versions
US7902387B2 (en
US20090270642A1 (en
Inventor
Achampeta Prasad
Roy Swaringen
John Reid
Robert Moriarty
Akhila Sahoo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Kythera Biopharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JOP/2018/0077A priority Critical patent/JOP20180077A1/en
Application filed by Kythera Biopharmaceuticals LLC filed Critical Kythera Biopharmaceuticals LLC
Priority to MX2012006571A priority patent/MX360094B/en
Priority to CR20170070A priority patent/CR20170070A/en
Priority to PT111818316T priority patent/PT2407475E/en
Priority to KR1020147035206A priority patent/KR101598402B1/en
Priority to MYPI20095366A priority patent/MY160040A/en
Priority to CA2789109A priority patent/CA2789109C/en
Priority to DK11181831.6T priority patent/DK2407475T3/en
Priority to HUE11181831A priority patent/HUE025909T2/en
Priority to CA2690841A priority patent/CA2690841C/en
Priority to AU2008265721A priority patent/AU2008265721B2/en
Priority to EP11181831.6A priority patent/EP2407475B1/en
Priority to KR1020097026748A priority patent/KR20100031512A/en
Priority to KR1020137027503A priority patent/KR20130133881A/en
Priority to MX2009013664A priority patent/MX2009013664A/en
Priority to KR1020187014779A priority patent/KR101916024B1/en
Priority to EP08771400A priority patent/EP2069383A2/en
Priority to JP2010513387A priority patent/JP2010530876A/en
Priority to NZ581081A priority patent/NZ581081A/en
Priority to PCT/US2008/067391 priority patent/WO2008157635A2/en
Priority to CN201610262072.2A priority patent/CN106083969B/en
Priority to JOP/2008/0286A priority patent/JO3172B1/en
Priority to ES11181831.6T priority patent/ES2550504T3/en
Priority to CN201810072485.3A priority patent/CN108191940B/en
Priority to EP15173458.9A priority patent/EP3002290B1/en
Priority to EA201000032A priority patent/EA020806B1/en
Priority to TW097122750A priority patent/TWI503327B/en
Priority to KR1020167004581A priority patent/KR20160025044A/en
Priority to CN201610262578.3A priority patent/CN106146594A/en
Priority to ES15173458T priority patent/ES2826429T3/en
Priority to CN200880019212A priority patent/CN101711254A/en
Priority to KR1020167035728A priority patent/KR101863131B1/en
Priority to PL11181831T priority patent/PL2407475T3/en
Priority to SI200831482T priority patent/SI2407475T1/en
Priority to BRPI0813140A priority patent/BRPI0813140C1/en
Priority to KR1020187031750A priority patent/KR102061001B1/en
Priority to TW104118229A priority patent/TWI503396B/en
Priority to ARP080102625A priority patent/AR067440A1/en
Assigned to KYTHERA BIOPHARMACEUTICALS, INC. reassignment KYTHERA BIOPHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: REID, JOHN GREGORY, MORIARTY, ROBERT M, PRASAD, ACHAMPETA RATHAN, SWARINGEN, ROY A, JR.
Assigned to KYTHERA BIOPHARMACEUTICALS, INC. reassignment KYTHERA BIOPHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: SAHOO, AKHILA KUMAR
Publication of US20090270642A1 publication Critical patent/US20090270642A1/en
Priority to US12/613,969 priority patent/US7994351B2/en
Priority to ZA2009/07928A priority patent/ZA200907928B/en
Priority to IL202203A priority patent/IL202203B/en
Priority to HK12106564.9A priority patent/HK1165807A1/en
Priority to CR11174A priority patent/CR11174A/en
Priority to SM201000003T priority patent/SMP201000003B/en
Publication of US20100179337A2 publication Critical patent/US20100179337A2/en
Priority to US13/010,727 priority patent/US8362285B2/en
Publication of US7902387B2 publication Critical patent/US7902387B2/en
Application granted granted Critical
Priority to US13/115,889 priority patent/US8367852B2/en
Priority to US13/730,533 priority patent/US9150607B2/en
Priority to JP2013007521A priority patent/JP5589102B2/en
Priority to US13/752,175 priority patent/US20130267721A1/en
Priority to US14/696,204 priority patent/US10053486B2/en
Priority to HRP20150879TT priority patent/HRP20150879T1/en
Priority to CY20151100828T priority patent/CY1116700T1/en
Priority to HK16111527.1A priority patent/HK1223372A1/en
Priority to US16/051,409 priority patent/US10633412B2/en
Assigned to KYTHERA BIOPHARMACEUTICALS, LLC reassignment KYTHERA BIOPHARMACEUTICALS, LLC CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: KYTHERA BIOPHARMACEUTICALS, INC.
Assigned to ALLERGAN SALES, LLC reassignment ALLERGAN SALES, LLC MERGER AND CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: ALLERGAN SALES, LLC, KYTHERA BIOPHARMACEUTICALS, LLC
Priority to US16/856,374 priority patent/US11008363B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0011—Androstane derivatives substituted in position 17 by a keto group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Definitions

  • the present invention relates to the synthesis of deoxycholoic acid and pharmaceutically acceptable salts and intermediates thereof.
  • fat removal therapies typically require 4-6 sessions.
  • This localized fat removal without the need for surgery is beneficial not only for therapeutic treatment relating to pathological localized fat deposits (e.g., dyslipidemias incident to medical intervention in the treatment of HIV), but also for cosmetic fat removal without the attendant risk inherent in surgery (e.g., liposuction).
  • pathological localized fat deposits e.g., dyslipidemias incident to medical intervention in the treatment of HIV
  • cosmetic fat removal without the attendant risk inherent in surgery e.g., liposuction.
  • Rotunda et al., Dermatol. Surgery 30: 1001-1008 (2004) (“Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution”) and Rotunda et al., J. Am. Acad. Dermatol. (2005: 973-978) (“Lipomas treated with subcutaneous deoxycholate injections”), both incorporated herein by reference.
  • bile acid preparations are commercially available at relatively low cost. This low cost is due to the fact that the bile acids are obtained from animal carcasses, particularly large animals such as cows and sheep. Importantly, as with all medicaments from animal sources, there is concern that the animal-derived bile acid products may contain animal pathogens and other harmful agents such as animal or microbial metabolites and toxins, including bacterial toxins such as pyrogens.
  • bile acids such as deoxycholic acids that are known from the outset to be free from moieties of animal origin (or pathogenic moieties capable of acting in an animal, particularly a mammal, and for human use, having a deleterious effect on a human), and other harmful agents such as animal or microbial metabolites, toxins, including bacterial toxins, such as pyrogens, for use as medicaments in humans.
  • the present invention provides methods and intermediates relating to the synthesis of deoxycholic acid and pharmaceutically acceptable salts thereof.
  • the synthetically prepared deoxycholic acid can be used in adipolytic therapy for fat removal.
  • FIG. 1 shows the similarity in dose-dependent decrease in cell survival of primary human adipocytes upon treatment with synthetic sodium deoxycholic acid of the present invention in comparison to bovine-derived sodium deoxycholate (Sigma).
  • compositions and methods comprising the compounds and methods include the recited elements, but not excluding others.
  • Consisting essentially of when used to define compositions and methods, shall mean excluding other elements of any essential significance to the compounds or method.
  • Consisting of shall mean excluding more than trace elements of other ingredients for claimed compounds and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention. Accordingly, it is intended that the methods and compounds can include additional steps and components (comprising) or alternatively include additional steps and compounds of no significance (consisting essentially of) or alternatively, intending only the stated methods steps or compounds (consisting of).
  • alkyl refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH 3 —), ethyl (CH 3 CH 2 —), n-propyl (CH 3 CH 2 CH 2 —), isopropyl ((CH 3 ) 2 CH—), n-butyl (CH 3 CH 2 CH 2 CH 2 —), isobutyl ((CH 3 ) 2 CHCH 2 —), sec-butyl ((CH 3 )(CH 3 CH 2 )CH—), t-butyl ((CH 3 ) 3 C—), n-pentyl (CH 3 CH 2 CH 2 CH 2 CH 2 —), and neopentyl ((CH 3 ) 3 CCH 2 —).
  • oxidizing agent refers to a reagent which can accept electrons in an oxidation-reduction reaction. In this way, oxygen can be added to a molecule or hydrogen can be removed from a molecule.
  • reducing agent refers to a reagent which can donate electrons in an oxidation-reduction reaction, allowing hydrogen to be added to a molecule.
  • acetylating reagent refers to a reagent in which can add an acetyl (Ac) group CH 3 C(O)— to an alcohol moiety of a molecule.
  • the term “acid” refers to regents capable of donating H + .
  • Lewis acids refers to an electron pair acceptor.
  • Lewis acids include oraganometallic reagents such as alkyl aluminum halides (e.g. Et 2 AlCl and MeAlCl 2 ).
  • Hydrogenation conditions refers to suitable conditions and catalysts for introducing H 2 across one or more double bonds.
  • Hydrogenation catalysts include those based on platinum group metals (platinum, palladium, rhodium, and ruthenium) such as Pd/C and PtO 2 .
  • olefination reagent refers to regents that react with ketones to form the corresponding olefins.
  • olefin forming conditions refers to suitable conditions for carryout such transformations. Examples of such reagents include Wittig regeants and Wittig olefination conditions.
  • DCA deoxycholic acid
  • the present invention also provides the following intermediates shown in Scheme 1 below wherein Ac and R are as defined above.
  • the hydrogenation conditions of part (a) comprises a Pd/C catalyst.
  • the acid of part (b) is a mineral acid.
  • the mineral acid is H 2 SO 4 .
  • the reducing agent of part (c) is LiAl(OtBu) 3 H.
  • the two carbon olefination reagent of part (d) is a Wittig agent such as Ph 3 PCH 2 CH 3 + Br ⁇ .
  • the protecting group P of compound 1.6-2.1 is —C(O)CH 3 .
  • compound 1.5 is exposed to acylation conditions to form 1.6a, such as by treatment of 1.5 with acetic anhydride and an organic base such as Et 3 N, pyridine, and/or dimethylaminopyridine.
  • the Lewis acid of part (f) is EtAlCl 2 .
  • the alkylpropiolate of part (f) is methylpropriolate.
  • the alkyl acrylate of part (f) is methylacrylate.
  • the hydrogenation conditions of part (g) comprises a PtO 2 or Pd/C catalyst.
  • the oxidizing agent of part (h) is CrO 3 .
  • the hydrogenation conditions of part (i) comprises a Pd/C catalyst.
  • the reducing agent of part (j) is LiAl(OtBu) 3 H.
  • the deprotection and hydrolysis conditions of part (k) when P is —C(O)CH 3 comprises reacting compound 2.1a with an alkali earth hydroxide, alkali earth alkoxide, or a mixture of both.
  • the alkali earth alkoxide is LiOH.
  • salts of deocycholoic acid can be prepared by reaction with an alkali earth metal alkoxide or hydroxide.
  • Salts of deocycholoic acid include the sodium (Na + ), potassium (K + ), and lithium (Li + ) salts.
  • an intermediate compound selected from the group consisting of
  • the compounds of preferred embodiments can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions.
  • Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis , Third Edition, Wiley, New York, 1999, and references cited therein.
  • the starting materials and reagents for the reactions described herein are generally known compounds or can be prepared by known procedures or obvious modifications thereof.
  • many of the starting materials and reagents are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wis., USA), Bachem (Torrance, Calif., USA), Emka-Chem or Sigma (St. Louis, Mo., USA).
  • the various starting materials, intermediates, and compounds of the preferred embodiments may be isolated and purified where appropriate using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. Characterization of these compounds may be performed using conventional methods such as by melting point, mass spectrum, nuclear magnetic resonance, and various other spectroscopic analyses.
  • TLC mobile phase 30%—EtOAc in DCM.
  • TLC mobile phase 30%—EtOAc in DCM.
  • TLC mobile phase 30%—EtOAc in DCM (30%).
  • IR (KBr) 3463, 2960, 2871, 1729, 1366, 1165, 1084, 1041 cm ⁇ 1 .
  • the reaction was quenched by adding saturated aqueous NH 4 Cl solution (75 mL). The phases were separated and the aqueous layer was extracted three times with EtOAc (3 ⁇ 150 mL). The organic fractions were combined, washed with saturated brine solution (100 mL), dried over Na 2 SO 4 (75 g), and filtered. The filtrate was concentrated under vacuum and the crude solid was purified by column chromatography [49 mm (W) ⁇ 600 mm (L), 60-120 mesh silica, 300 g] eluting with ethyl acetate/hexanes (1:9). The fractions containing product were combined and concentrated, providing compound 1.5 (19.1 g, 80.0%) as a white solid.
  • TLC mobile phase 30%—EtOAc in DCM.
  • IR (CHCl 3 ) 3304, 3033, 2925, 2863, 1449, 1368, 1040, 823 cm ⁇ 1 .
  • TLC mobile phase 10%—EtOAc in hexanes.
  • IR (CHCl 3 ) 3440, 3035, 1730, 1451, 1367, 1258, 1028 cm ⁇ 1 .
  • TLC mobile phase 10%—EtOAc in hexanes.
  • IR (KBr) 3443, 3030, 2930, 1719, 1650, 1247, 1359, 1032, 1170 cm ⁇ 1 .
  • TLC mobile phase 10%—EtOAc in hexanes.
  • IR (KBr) 3435, 3039, 2941, 1729, 1448, 1435, 1252, 1022 cm ⁇ 1 .
  • TLC mobile phase 10%—EtOAc in hexanes.
  • TLC mobile phase 20%—EtOAc in hexanes.
  • IR 3437, 3045, 2946, 2870, 1729, 1680, 1252, 1168, 1020, cm ⁇ 1 .
  • TLC mobile phase 20%—EtOAc in hexanes.
  • TLC mobile phase 30%—EtOAc in hexanes.
  • IR (KBr) 3621, 2938, 2866, 1742, 1730, 1262, 1162, 1041, cm ⁇ 1 .
  • DCA Deoxycholic Acid
  • TLC mobile phase 10%—Methanol in DCM.
  • IR 3363, 2933, 2863, 1694, 1453, 1372, 1042, cm ⁇ 1 .
  • Serum-free RPMI medium Mediatech cat# 17-105-CV
  • Adipocytes arrived differentiated and at a density of 13,000 cells per well in a 96 well plate. Two plates were received and each treated with the same samples. Cells were incubated for 24 hours at 37° C. with 5% CO 2 .
  • a 1% stock solution of each bile acid (synthetic and non-synthetic DCA) were made by dissolving 20 mg into 2 mL media (serum-free). Using the 1% stock solution, the following 11 solutions were prepared by dilution: 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.035%, 0.04%, 0.05%, 0.06%, and 0.1%, as well as 0% (media only).
  • Cells were washed 2 ⁇ with 150 ⁇ L of room temperature 1 ⁇ PBS (phosphate buffered saline). Media and then PBS were removed from the wells in a 96 well plate by turning the plate upside down and decanting the liquid into a container. After the last PBS wash, 80 ⁇ L of sample was added per well. Each concentration of a specific bile acid was added to 8 wells and incubated for 1 hour at 37° C. with 5% CO 2 . Plates were then removed from incubator and solution was decanted.
  • PBS phosphate buffered saline

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Synthetic methods for preparing deoxycholic acid and intermediates thereof are provided.

Description

    CROSS REFERENCE TO RELATED APPLICATION
  • This application claims the benefit under 35 U.S.C. 119(a) of United Kingdom Application Serial No. 0807615.0 filed Apr. 25, 2008, which is hereby incorporated by reference into this application in its entirety.
    • BACKGROUND OF THE INVENTION
  • 1. Field of the Invention
  • The present invention relates to the synthesis of deoxycholoic acid and pharmaceutically acceptable salts and intermediates thereof.
  • 2. State of the Art
  • Rapid removal of body fat is an age-old ideal, and many substances have been claimed to accomplish such results, although few have shown results. “Mesotherapy”, or the use of injectables for the removal of fat, is not widely accepted among medical practitioners due to safety and efficacy concerns, although homeopathic and cosmetic claims have been made since the 1950's. Mesotherapy was originally conceived in Europe as a method of utilizing cutaneous injections containing a mixture of compounds for the treatment of local medical and cosmetic conditions. Although mesotherapy was traditionally employed for pain relief, its cosmetic applications, particularly fat and cellulite removal, have recently received attention in the United States. One such reported treatment for localized fat reduction, which was popularized in Brazil and uses injections of phosphatidylcholine, has been erroneously considered synonymous with mesotherapy. Despite its attraction as a purported “fat-dissolving” injection, the safety and efficacy of these cosmetic treatments remain ambiguous to most patients and physicians. See, Rotunda, A. M. and M. Kolodney, Dermatologic Surgery 32: 465-480 (2006) (“Mesotherapy and Phosphatidylcholine Injections: Historical Clarification and Review”).
  • Recently published literature reports that the bile acid deoxycholic acid has fat removing properties when injected into fatty deposits in vivo. See, WO 2005/117900 and WO 2005/112942, as well as US2005/0261258; US2005/0267080; US2006/127468; and US20060154906, all incorporated herein by reference in their entirety including figures). Deoxycholate injected into fat tissue has the effects of: 1) degrading fat cells via a cytolytic mechanism; and 2) causing skin tightening. Both of these effects are required to mediate the desired aesthetic corrections (i.e., body contouring). Because deoxycholate injected into fat is rapidly inactivated by exposure to protein and then rapidly returns to the intestinal contents, its effects are spatially contained. As a result of this attenuation effect that confers clinical safety, fat removal therapies typically require 4-6 sessions. This localized fat removal without the need for surgery is beneficial not only for therapeutic treatment relating to pathological localized fat deposits (e.g., dyslipidemias incident to medical intervention in the treatment of HIV), but also for cosmetic fat removal without the attendant risk inherent in surgery (e.g., liposuction). See, Rotunda et al., Dermatol. Surgery 30: 1001-1008 (2004) (“Detergent effects of sodium deoxycholate are a major feature of an injectable phosphatidylcholine formulation used for localized fat dissolution”) and Rotunda et al., J. Am. Acad. Dermatol. (2005: 973-978) (“Lipomas treated with subcutaneous deoxycholate injections”), both incorporated herein by reference.
  • Pharmaceutical grade bile acid preparations are commercially available at relatively low cost. This low cost is due to the fact that the bile acids are obtained from animal carcasses, particularly large animals such as cows and sheep. Importantly, as with all medicaments from animal sources, there is concern that the animal-derived bile acid products may contain animal pathogens and other harmful agents such as animal or microbial metabolites and toxins, including bacterial toxins such as pyrogens.
  • Currently, the concerns regarding animal-derived products containing animal pathogens and other harmful agents has been addressed by sourcing from isolated and inspected animals. For example, deoxycholic acid from animals in New Zealand are a source of bile acids for human use under US regulatory regimes, as long as the animals continue to remain isolated and otherwise free of observable pathogens.
  • There remains a need for suitable quantities of efficacious bile acids such as deoxycholic acids that are known from the outset to be free from moieties of animal origin (or pathogenic moieties capable of acting in an animal, particularly a mammal, and for human use, having a deleterious effect on a human), and other harmful agents such as animal or microbial metabolites, toxins, including bacterial toxins, such as pyrogens, for use as medicaments in humans.
    • SUMMARY OF THE INVENTION
  • The present invention provides methods and intermediates relating to the synthesis of deoxycholic acid and pharmaceutically acceptable salts thereof. The synthetically prepared deoxycholic acid can be used in adipolytic therapy for fat removal.
    • BRIEF DESCRIPTION OF THE FIGURE
  • FIG. 1 shows the similarity in dose-dependent decrease in cell survival of primary human adipocytes upon treatment with synthetic sodium deoxycholic acid of the present invention in comparison to bovine-derived sodium deoxycholate (Sigma).
    • DETAILED DESCRIPTION OF THE INVENTION
  • Throughout this disclosure, various publications, patents and published patent specifications are referenced by an identifying citation. The disclosures of these publications, patents and published patent specifications are hereby incorporated by reference into the present disclosure to more fully describe the state of the art to which this invention pertains.
  • As used herein, certain terms may have the following defined meanings. As used in the specification and claims, the singular form “a,” “an” and “the” include singular and plural references unless the context clearly dictates otherwise.
  • Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term “about.” Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations. Each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
  • As used herein, the term “comprising” is intended to mean that the compounds and methods include the recited elements, but not excluding others. “Consisting essentially of” when used to define compositions and methods, shall mean excluding other elements of any essential significance to the compounds or method. “Consisting of” shall mean excluding more than trace elements of other ingredients for claimed compounds and substantial method steps. Embodiments defined by each of these transition terms are within the scope of this invention. Accordingly, it is intended that the methods and compounds can include additional steps and components (comprising) or alternatively include additional steps and compounds of no significance (consisting essentially of) or alternatively, intending only the stated methods steps or compounds (consisting of).
  • The term “alkyl” refers to monovalent saturated aliphatic hydrocarbyl groups having from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms. This term includes, by way of example, linear and branched hydrocarbyl groups such as methyl (CH3—), ethyl (CH3CH2—), n-propyl (CH3CH2CH2—), isopropyl ((CH3)2CH—), n-butyl (CH3CH2CH2CH2—), isobutyl ((CH3)2CHCH2—), sec-butyl ((CH3)(CH3CH2)CH—), t-butyl ((CH3)3C—), n-pentyl (CH3CH2CH2CH2CH2—), and neopentyl ((CH3)3CCH2—).
  • The term “oxidizing agent” refers to a reagent which can accept electrons in an oxidation-reduction reaction. In this way, oxygen can be added to a molecule or hydrogen can be removed from a molecule.
  • The term “reducing agent” refers to a reagent which can donate electrons in an oxidation-reduction reaction, allowing hydrogen to be added to a molecule.
  • The term “acetylating reagent” refers to a reagent in which can add an acetyl (Ac) group CH3C(O)— to an alcohol moiety of a molecule.
  • The term “acid” refers to regents capable of donating H+.
  • The term “Lewis acid” refers to an electron pair acceptor. Lewis acids include oraganometallic reagents such as alkyl aluminum halides (e.g. Et2AlCl and MeAlCl2).
  • The term “hydrogenation conditions” refers to suitable conditions and catalysts for introducing H2 across one or more double bonds. Hydrogenation catalysts include those based on platinum group metals (platinum, palladium, rhodium, and ruthenium) such as Pd/C and PtO2.
  • The term “olefination reagent” refers to regents that react with ketones to form the corresponding olefins. The term “olefin forming conditions” refers to suitable conditions for carryout such transformations. Examples of such reagents include Wittig regeants and Wittig olefination conditions.
  • The numbering of the steroidal scaffold as used herein follows the general convention:
    Figure US20100179337A2-20100715-C00001
  • Accordingly, provided is a method for preparing deoxycholic acid (DCA) or a pharmaceutically acceptable salt thereof:
    Figure US20100179337A2-20100715-C00002
    said method comprising
  • (a) reacting 9α-hydroxyandrost-4-en-3,17-dione 1.0 with H2 under hydrogenation conditions to form compound 1.1
    Figure US20100179337A2-20100715-C00003
  • (b) reacting compound 1.1 with acid to form compound 1.2
    Figure US20100179337A2-20100715-C00004
  • (c) reacting compound 1.2 a reducing agent to form compound 1.3 a mixture of 1.3 and
    Figure US20100179337A2-20100715-C00005
  • (d) reacting compound 1.3 with a two carbon olefination reagent under olefin forming conditions to form compound 1.5
    Figure US20100179337A2-20100715-C00006
  • (e) converting compound 1.5 to a compound of formula 1.6 wherein P is a protecting group
    Figure US20100179337A2-20100715-C00007
  • (f) reacting a compound of formula 1.6 with an alkylpropiolate CH2CH2C(O)OR or an alkyl acrylate CH2═CHC(O)OR wherein R is alkyl in the presence of a Lewis acid to form a compound of formula 1.7 wherein P is a protecting group, R is a alkyl, and the dashed line
    Figure US20100179337A2-20100715-P00001
    is a single or double bond;
    Figure US20100179337A2-20100715-C00008
  • (g) reacting a compound of formula 1.7 with H2 under hydrogenation conditions to form a compound of formula 1.8 wherein P is a protecting group and R is alkyl
    Figure US20100179337A2-20100715-C00009
  • (h) reacting compound of formula 1.8 with an oxidizing agent to form a compound of formula 1.9 wherein P is a protecting group and R is alkyl
    Figure US20100179337A2-20100715-C00010
  • (i) reacting a compound of formula 1.9 with H2 under hydrogenation conditions to form compound of formula 2.0 wherein P is a protecting group and R is alkyl
    Figure US20100179337A2-20100715-C00011
  • (j) reacting compound of formula 2.0 with a reducing agent to form a compound of formula 2.1 wherein P is a protecting group and R is alkyl
    Figure US20100179337A2-20100715-C00012
  • (k) exposing compound of formula 2.1 to deprotection and hydrolysis conditions to form deoxycholic acid.
  • The present invention also provides the following intermediates shown in Scheme 1 below wherein Ac and R are as defined above.
    Figure US20100179337A2-20100715-C00013
    Figure US20100179337A2-20100715-C00014
    Figure US20100179337A2-20100715-C00015
  • In one embodiment, the hydrogenation conditions of part (a) comprises a Pd/C catalyst.
  • In one embodiment, the acid of part (b) is a mineral acid. In some aspects, the mineral acid is H2SO4.
  • In one embodiment, the reducing agent of part (c) is LiAl(OtBu)3H.
  • In one embodiment, the two carbon olefination reagent of part (d) is a Wittig agent such as Ph3PCH2CH3 +Br−.
  • In one embodiment, the protecting group P of compound 1.6-2.1 is —C(O)CH3. In some aspects compound 1.5 is exposed to acylation conditions to form 1.6a, such as by treatment of 1.5 with acetic anhydride and an organic base such as Et3N, pyridine, and/or dimethylaminopyridine.
  • In one embodiment, the Lewis acid of part (f) is EtAlCl2.
  • In one embodiment, the alkylpropiolate of part (f) is methylpropriolate.
  • In one embodiment, the alkyl acrylate of part (f) is methylacrylate.
  • In one embodiment, the hydrogenation conditions of part (g) comprises a PtO2 or Pd/C catalyst.
  • In one embodiment, the oxidizing agent of part (h) is CrO3.
  • In one embodiment, the hydrogenation conditions of part (i) comprises a Pd/C catalyst.
  • In one embodiment, the reducing agent of part (j) is LiAl(OtBu)3H.
  • In one embodiment, the deprotection and hydrolysis conditions of part (k) when P is —C(O)CH3 comprises reacting compound 2.1a with an alkali earth hydroxide, alkali earth alkoxide, or a mixture of both.
  • In one embodiment, the alkali earth alkoxide is LiOH.
  • In one embodiment, salts of deocycholoic acid can be prepared by reaction with an alkali earth metal alkoxide or hydroxide. Salts of deocycholoic acid include the sodium (Na+), potassium (K+), and lithium (Li+) salts.
  • In one embodiment, provided is an intermediate compound selected from the group consisting of
    • 9α-Hydroxy-5β-androstan-3,17-dione (1.1);
    • 5β-Androst-9(11)-en-3,17-dione (1.2);
    • (Z)-3α-Hydroxy-5β-pregna-9(11),17(20)-diene (1.5);
    • (Z)-3α-Acetoxy-5β-pregna-9(11),17(20)-diene (1.6);
    • (E)-Methyl 3α-acetoxy-5β-chol-9(11), 16,22-trien-24-oate (1.7a);
    • Methyl 3α-acetoxy-5β-chol-9(11), 16-dien-24-oate (1.7b);
    • Methyl 3α-hydroxy-5β-chol-9(11)-en-12-one-24-oate (1.9a); and
    • Methyl 3α-acetoxy-5β-cholan-12-one-24-oate (2.0a).
  • The compounds of preferred embodiments can be prepared from readily available starting materials using the following general methods and procedures. It will be appreciated that where typical or preferred process conditions (i.e., reaction temperatures, times, mole ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvent used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
  • Additionally, as will be apparent to those skilled in the art, conventional protecting groups may be necessary to prevent certain functional groups from undergoing undesired reactions. Suitable protecting groups for various functional groups as well as suitable conditions for protecting and deprotecting particular functional groups are well known in the art. For example, numerous protecting groups are described in T. W. Greene and G. M. Wuts, Protecting Groups in Organic Synthesis, Third Edition, Wiley, New York, 1999, and references cited therein.
  • The starting materials and reagents for the reactions described herein are generally known compounds or can be prepared by known procedures or obvious modifications thereof. For example, many of the starting materials and reagents are available from commercial suppliers such as Aldrich Chemical Co. (Milwaukee, Wis., USA), Bachem (Torrance, Calif., USA), Emka-Chem or Sigma (St. Louis, Mo., USA). Others may be prepared by procedures, or obvious modifications thereof, described in standard reference texts such as Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-15 (John Wiley and Sons, 1991), Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989), Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991), March's Advanced Organic Chemistry, (John Wiley and Sons, 4th Edition), and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989).
  • The various starting materials, intermediates, and compounds of the preferred embodiments may be isolated and purified where appropriate using conventional techniques such as precipitation, filtration, crystallization, evaporation, distillation, and chromatography. Characterization of these compounds may be performed using conventional methods such as by melting point, mass spectrum, nuclear magnetic resonance, and various other spectroscopic analyses.
  • The foregoing and other aspects of the embodiments disclosed herein may be better understood in connection with the following examples.
    • EXAMPLES
  • In the examples below and elsewhere in the specification, the following abbreviations have the indicated meanings. If an abbreviation is not defined, it has its generally accepted meaning.
    AcOH Acetic acid
    Ac2O Acetic anhydride
    CrO3 Chromium trioxide
    DCA Deoxycholic acid
    DCM (CH2Cl2) Dichloromethane
    DMF N,N-Dimethylformamide
    EtOAc Ethyl acetate
    EtAlCl2 Ethyl aluminum dichloride
    Hz Hertz
    HPLC High pressure liquid chromatography
    HCl Hydrochloric acid
    LiOH Lithium hydroxide
    Na2SO4 Sodium sulfate
    MHz Megahertz
    min Minutes
    MeOH Methanol
    mmol millimole
    mL milliliter
    mol mole
    Obs Observed
    HClO4 Perchloric acid
    PtO2 Platinum oxide
    Pd/C Palladium on carbon
    H2SO4 Sulphuric acid
    DMAP 4-Dimethylaminopyridine
    LiAl(OtBu)3H Lithium tri-tert-butoxyaluminum
    hydride
    KBr Potassium bromide
    K-OtBu Potassium tert-butoxide
    Rep Reported
    NaOH Sodium hydroxide
    THF Tetrahydrofuran
    TEA Triethylamine
    TLC Thin layer chromatography
    Wt Weight
    CONC Concentrated
    ACN Acetonitrile
    TFA Trifluoroacetic acid
  • General: All manipulations of oxygen- and moisture-sensitive materials were conducted with standard two-necked flame dried flasks under an argon or nitrogen atmosphere. Column chromatography was performed using silica gel (60-120 mesh). Analytical thin layer chromatography (TLC) was performed on Merck Kiesinger 60 F254 (0.25 mm) plates. Visualization of spots was either by UV light (254 nm) or by charring with a solution of sulfuric acid (5%) and p-anisaldehyde (3%) in ethanol.
  • Apparatus: Proton and carbon-13 nuclear magnetic resonance spectra (1H NMR and 13C NMR) were recorded on a Varian Mercury-Gemini 200 (1H NMR, 200 MHz; 13C NMR, 50 MHz) or a Varian Mercury-Inova 500 (1H NMR, 500 MHz; 13C NMR, 125 MHz) spectrometer with solvent resonances as the internal standards (1H NMR, CHCl3 at 7.26 ppm or DMSO at 2.5 ppm and DMSO-H2O at 3.33 ppm; 13C NMR, CDCl3 at 77.0 ppm or DMSO at 39.5 ppm). 1H NMR data are reported as follows: chemical shift (6, ppm), multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, br=broad, m=multiplet), coupling constants (Hz), and integration. Infrared spectra (FT-IR) were run on a JASCO-460+ model. Mass spectra were obtained with a Perkin Elmer API-2000 spectrometer using ES+ mode. Melting points were determined using a LAB-INDIA melting point measuring apparatus and are uncorrected. HPLC chromatograms were recorded using a SHIMADZU-2010 model with a PDA detector. Specific optical rotations were determined employing a JASCO-1020 at 589 nm and are uncorrected.
  • Chemicals: Unless otherwise noted, commercially available reagents were used without purification. Diethyl ether and THF were distilled from sodium/benzophenone. Laboratory grade anhydrous DMF, commercially available DCM, ethyl acetate and hexane were used.
    • Example 1 9α-Hydroxy-5β-androstan-3,17-dione (1.1)
  • Figure US20100179337A2-20100715-C00016
  • To a solution of 9α-hydroxyandrost-4-en-3,17-dione 1.0 (30.0 g, 99.3 mol) in DMF (150 mL) was added 10% of Pd/C (2.1 g) and the resulting slurry was hydrogenated in a Parr apparatus (60 psi) for 12 h. Upon complete disappearance of starting material, as evidenced by TLC, the crude reaction mixture was filtered through a small pad of Celite®, and the solvent was removed under vacuum to provide a colorless solid (30.0 g). This solid was combined with acetone (90 mL.) at 0° C. and the resulting slurry was stirred for 1 h. It was then filtered, washed with chilled (0° C.) acetone (30 mL) and dried under vacuum in the same filtration funnel at room temperature to afford compound 1.1 (26.0 g, 86%).
  • TLC: p-anisaldehyde charring, Rf for 1.1=0.48 and Rf for 1.0=0.30.
  • TLC mobile phase: 30%—EtOAc in DCM.
  • 1H NMR (500 MHz, CDCl3): δ 2.37-2.40 (m, 1H), 2.02-.2.11 (m, 2H), 1.31-1.91 (m, 19H), 0.96 (s, 3H), 0.84 (s, 3H).
  • 13C NMR (125 MHz, CDCl3): δ 221.0, 95.7, 80.1, 47.0, 43.6, 38.6, 38.5, 37.1, 35.9, 33.41, 32.9, 32.0, 27.9, 26.9, 21.5, 20.2, 20.0, 12.6.
  • Mass (m/z)=305.0[M++1], 322.0 [M++18].
  • IR (KBr)=3443, 2938, 1722, 1449, 1331, 1138 cm−1.
  • m.p 213-216° C. (from DMF and acetone)
  • [α]D+116 (c=1% in CHCl3).
  • ELSD Purity: more than 99%, ret. time=8.15, 9-HAD ret. time=3.88, 5α-isomer of Cmpd 121 ret. time=4.91 (Water symmetry 250×4.6 mm, 5 um, C18), Water:ACN (40:60).
    • Example 2 5β-Androst-9(11)-en-3,17-dione (1.2)
  • Figure US20100179337A2-20100715-C00017
  • To a solution of compound 1.1 (26.0 g, 85.4 mmol) in DCM (520 mL) was added concentrated sulfuric acid (7.53 g, 76.8 mmol) over 15 minutes under an inert atmosphere at 10° C. The temperature was raised to 25° C. and the resulting solution was stirred for 2 h. At this point no more starting material remained as evidenced by TLC. The reaction was quenched by the addition of 10% aqueous NaHCO3 solution (200 mL). The layers were separated and the aqueous layer was extracted twice with DCM (2×100 mL). The organic layers were combined and washed sequentially with water (100 mL) and saturated brine solution (100 mL). The organic phase was then dried over Na2SO4 (75 g) and filtered. The filtrate was evaporated under vacuum to provide compound 1.2 (23.0 g, 94%) as an off-white solid. This product was used “as is” in the next step without further purification.
  • TLC: p-anisaldehyde charring, Rf for 1.2=0.76 and Rf for 1.1=0.44.
  • TLC mobile phase: 30%—EtOAc in DCM.
  • 1H NMR (500 MHz, CDCl3): δ=5.61 (s, 1H), 2.47-2.57 (m, 2H), 2.24-2.42 (m, 4H), 2.05-2.20 (m, 3H), 1.86-1.99 (m, 2H), 1.84-1.85 (d, J=6 Hz, 1H), 1.57-1.63 (m, 5H), 1.37-1.40 (d, J=13.5 Hz, 1H) 1.25-1.28 (dd, J=4.0, 13.5 Hz, 1H), 1.17 (s, 3H) 0.85 (s, 3H).
  • 13C NMR (125 MHz, CDCl3): δ=221.3, 212.8, 140.1, 118.5, 48.5, 45.9, 44.3, 43.5, 39.0, 38.0, 37.3, 36.1, 35.8, 33.3, 28.8, 26.0, 25.5, 22.5, 13.9.
  • Mass (m/z)=287 [M++1], 304 [M++18].
  • IR (KBr)=3450, 2913, 1737, 1707, 1413, 1403, 1207 cm−1.
  • m.p.=143.4-145.9° C. (from DCM)
  • [α]D=+142 (c=1% in CHCl3).
  • ELSD Purity: 99.7%, Retention time=5.04, (Inertsil ODS 3V 250×4.6 mm, 5 um), ACN: 0.1% TFA in water (90:10).
    • Example 3 3α-Hydroxy-5β-androst-9(11)-en-1,7-one (1.3)
  • Figure US20100179337A2-20100715-C00018
  • A THF solution of lithium tri-tert-butoxyaluminum hydride (1.0 M, 84.4 mL, 84.4 mmol) was added to a cold (−40° C.) solution of compound 1.2 (23.0 g, 80.4 mmol) in THF (230 mL) under an inert atmosphere. The resulting reaction mixture was stirred for 2 h. At this point the reaction was determined to be complete, as evidenced by TLC, and the reaction mixture was quenched by adding a mixture of 1N HCl (200 mL) and ethyl acetate (230 mL). The resulting two phase mixture was separated and the aqueous layer was extracted twice with ethyl acetate (2×100 mL). The organic phases were combined and washed sequentially with water (150 mL) and saturated brine solution (100 mL). The organic phase was then dried over Na2SO4 (75 g) and filtered. The filtrate was evaporated under vacuum to afford compound 1.3 (23.0 g) as an off-white solid. The above crude product was used “as is” in the next step without purification.
  • TLC: p-anisaldehyde charring, Rf for 1.3=0.44 and Rf for 1.2=0.74.
  • TLC mobile phase: 30%—EtOAc in DCM (30%).
  • 1H NMR (500 MHz, CDCl3): δ=5.41-5.42 (d, J=6.0 Hz, 1H), 3.65-3.66 (m, 1H), 2.43-2.48 (m, 1H), 1.98-2.18 (m, 6H), 1.74 (s, 2H), 1.48-1.56 (m, 5H), 1.377-1.45 (m, 3H), 1.18-1.28 (m, 3H), 1.08 (s, 3H), 0.80 (s, 3H)
  • 13C NMR (125 MHz, CDCl3): δ=222.0, 140.9, 118.3, 71.9, 48.6, 45.9, 41.7, 38.8, 37.8, 36.2, 36.0, 35.7, 33.4, 31.7, 29.5, 26.5, 26.0, 22.7, 13.9.
  • Mass (m/z)=289.0 [M++1], 306.0 [M++18].
  • IR (KBr)=3463, 2960, 2871, 1729, 1366, 1165, 1084, 1041 cm−1.
  • m.p.=165-167.5° C. (EtOAc/hexanes mixture).
  • [α]D=+161 (c=1% in CHCl3).
  • ELSD Purity: ˜93%, Retention time=5.23, (Inertsil ODS 3V 250×4.6 mm, 5 um), ACN: 0.1% TFA in water (90:10).
    • Example 4 (Z)-3α-Hydroxy-5β-pregna-9(11),17(20)-diene (1.5)
  • Figure US20100179337A2-20100715-C00019
  • A solution of potassium tert-butoxide in THF (1 M, 230 mL, 231 mmol) was added drop wise to a suspension of ethyltriphenylphosphonium bromide (88.7 g, 239 mmol) in THF (150 mL) over 1 h at 25° C. The resulting dark red colored mixture was stirred for an additional 1 h at 25° C. A solution of compound 1.3 (23.0 g, 79.7 mmol) in THF (230 mL) was added slowly to the red-colored mixture at 25° C. The resulting mixture was stirred for 3-4 h, at which point it was determined to be complete by TLC. The reaction was quenched by adding saturated aqueous NH4Cl solution (75 mL). The phases were separated and the aqueous layer was extracted three times with EtOAc (3×150 mL). The organic fractions were combined, washed with saturated brine solution (100 mL), dried over Na2SO4 (75 g), and filtered. The filtrate was concentrated under vacuum and the crude solid was purified by column chromatography [49 mm (W)×600 mm (L), 60-120 mesh silica, 300 g] eluting with ethyl acetate/hexanes (1:9). The fractions containing product were combined and concentrated, providing compound 1.5 (19.1 g, 80.0%) as a white solid.
  • TLC: p-anisaldehyde charring, Rf for 1.5=0.72 and Rf for 1.3=0.46.
  • TLC mobile phase: 30%—EtOAc in DCM.
  • 1H NMR (500 MHz, CDCl3): δ=5.38 (s, 1H), 5.18-5.19 (d, J=6.5 Hz, 1H), 3.62-3.66 (m, 1H), 2.35-2.38 (d, J=15 Hz, 3H), 2.23-2.25 (m, 1H), 1.97-2.07 (m, 3H), 1.64-1.75 (m, 6H), 1.32-1.55 (m, 6H), 1.17-1.24 (m, 4H), 1.06 (s, 3H), 0.79 (s, 3H).
  • 13CNMR (125 MHz, CDCl3): δ=150.1, 140.6, 119.6, 114.2, 72.2, 53.6, 42.0, 41.9, 39.6, 38.6, 37.9, 35.7, 35.6, 31.9, 31.8, 29.5, 26.9, 26.8, 25.5, 16.9, 13.3.
  • Mass (m/z)=301[M++1], 318[M++18].
  • IR (CHCl3)=3304, 3033, 2925, 2863, 1449, 1368, 1040, 823 cm−1.
  • mp=146-147.3° C. (EtOAc/hexanes mixture).
  • [α]D=+84.4 (c=1% in CHCl3).
  • ELSD Purity: 99.8%, Retention time=16.07, (Inertsil ODS 3V 250×4.6 mm, 5 um), ACN: 0.1% TFA in water (90:10).
    • Example 5 (Z)-3α-Acetoxy-5β-pregna-9(11),17(20)-diene (1.6a)
  • Figure US20100179337A2-20100715-C00020
  • Compound 1.5 (19.0 g, 63 mmol) was dissolved in CH2Cl2 (380 mL). Triethylamine (17.6 mL, 126.6 mmol), DMAP (0.772 g, 6 mmol) and acetic anhydride (8.98 mL, 94 mmol) were added sequentially at 25° C. under a nitrogen atmosphere. The resulting solution was stirred for 2 h at 25° C., at which point the reaction was determined by TLC to be complete. The reaction was quenched by the addition of ice-water (100 mL) and the phases were separated. The aqueous layer was extracted three times with DCM (3×150 mL). The organic fractions were combined and washed with saturated brine solution (100 mL), dried over anhydrous Na2SO4 (50 g), and filtered. The filtrate was concentrated under vacuum to afford compound 1.6a (22.0 g, 95% yield) as an off-white solid.
  • TLC: p-anisaldehyde charring, Rf for 1.6=0.5 and Rf for 1.5=0.15.
  • TLC mobile phase: 10%—EtOAc in hexanes.
  • 1H NMR (500 MHz, CDCl3): δ=5.38 (s, 1H), 5.18-5.20 (d, J=6.5 Hz, 1H), 4.72-4.76 (m, 1H), 2.35-2.40 (m, 3H), 2.22-2.25 (m, 1H), 2.03-2.09 (m, 3H), 2.01 (s, 3H), 1.49-1.98 (m, 10H), 1.31-1.41 (m, 2H), 1.16-1.27 (m, 3H), 1.07 (s, 3H), 0.79 (s, 3H).
  • 13C NMR (125 MHz, CDCl3): δ=170.5, 150.0, 140.4, 119.6, 114.3, 74.7, 53.5, 42.0, 41.7, 39.6, 38.6, 35.6, 35.3, 33.8, 31.9, 29.5, 27.8, 26.7, 26.6, 25.5, 21.3, 16.9, 13.2
  • Mass (m/z)=342.9 [M++1], 360 [M++18].
  • IR (CHCl3)=3440, 3035, 1730, 1451, 1367, 1258, 1028 cm−1.
  • mp=93.9-97.8° C. (EtOAc/hexanes mixture)
  • [α]D=+109 (c=1% in CHCl3).
  • HPLC purity: 97.62%; Retention time=17.7, (Zorbax SB, C18; 250×4.6 mm, 5 um), ACN: 0.1% TFA in water (90:10).
    • Example 6 (E)-Methyl 3α-acetoxy-5β-chol-9(11), 16,22-trien-24-oate (1.7a)
  • Figure US20100179337A2-20100715-C00021
  • Ethyl aluminum dichloride (104.5 mL, 192 mmol, 1.8 M in toluene) was added to a solution of methyl propiolate (13.58 mL, 153 mmol) in DCM (100 mL) at 0° C. under inert atmosphere. The resulting solution was stirred for 15 min and then compound 1.6a (22 g, 64.3 mmol) was added. After stirring for an additional 20 min at 0° C., the temperature was raised to 25° C. and held there for a further 18 h. At this point the reaction was determined to be complete by TLC, and the mixture was poured into cold (0° C.) water (200 mL). The phases were separated and the aqueous layer was extracted with DCM (150 mL). The organic layers were combined and washed sequentially with water (200 mL) and saturated brine solution (100 mL). It was then dried over anhydrous Na2SO4 (40 g) and filtered. The filtrate was concentrated under vacuum and the resulting solid was purified by slurring in methanol (280 mL) to provide compound 1.7a (17.5 g 68%) as a white solid.
  • TLC: p-anisaldehyde charring, Rf for 1.7a=0.32 and Rf for 1.6a=0.5.
  • TLC mobile phase: 10%—EtOAc in hexanes.
  • 1H NMR (500 MHz, CDCl3): δ=6.92-6.926 (q, J=7.5, 15.5 Hz, 1H), 5.80-5.83 (d, J=16 Hz, 1H), 5.37-5.43 (m, 2H), 4.73-4.75 (m, 1H), 3.73 (s, 3H), 3.02-3.04 (t, J=6.5 Hz, 1H), 2.15-2.23 (m, 3H), 2.05-2.08 (m, 3H), 2.01 (s, 3H), 1.48-1.99 (m, 8H), 1.24-1.34 (m, 2H), 1.20-1.21 (d, J=5 Hz, 3H), 1.11-1.17 (m, 1H), 1.07 (s, 3H), 0.67 (s, 3H).
  • 13C NMR (125 MHz, CDCl3): δ=170.5, 167.2, 155.0, 153.7, 141.6, 124.0, 118.8, 118.7, 74.6, 53.9, 51.3, 45.7, 41.7, 38.8, 37.1, 35.5, 35.3, 34.6, 33.7, 31.8, 29.5, 27.7, 26.5, 26.5, 21.3, 19.7, 15.7.
  • Mass (m/z)=444.0 [M++18].
  • IR (KBr)=3443, 3030, 2930, 1719, 1650, 1247, 1359, 1032, 1170 cm−1.
  • m.p.=114-116° C. (from methanol)
  • [α]D=+102 (c=1% in CHCl3).
  • ELSD Purity: 99.7%, Retention time=19.57, (Inertsil ODS 3V 250×4.6 mm, 5 um), ACN: 0.1% TFA in water (90:10).
    • Example 7 Methyl 3α-acetoxy-5β-chol-9(11)-en-24-oate (1.8a)
  • Figure US20100179337A2-20100715-C00022
  • To a solution of compound 1.7a (17.5 g, 41 mmol) in EtOAc (350 mL) was added PtO2 (4.37 g), and the resulting slurry was hydrogenated in a Parr apparatus (70 psi) for 14-16 h. At this point the reaction was determined to be complete by TLC. The mixture was filtered through a small plug of Celite® and the solvent was removed under vacuum, affording compound 1.8a (17.0 g, 96.0%) as a white solid. The above product was used in the next step without further purification.
  • TLC: p-anisaldehyde charring, Rf for 1.8a=0.32 and Rf for 1.7a=0.30.
  • TLC mobile phase: 10%—EtOAc in hexanes.
  • 1H NMR (500 MHz, CDCl3): δ=5.31 (s, 1H), 4.73 (m, 1H), 3.66 (s, 3H), 2.03-2.37 (m, 7H), 2.01 (s, 3H), 1.09-1.98 (m, 18H), 1.06 (s, 3H), 0.91-0.92 (d, J=6.0 Hz, 3H), 0.59 (s, 3H).
  • 13C NMR (125 MHz, CDCl3): δ=174.6, 170.5, 139.8, 119.5, 74.8, 56.0, 53.3, 51.4, 41.9, 41.7, 40.9, 38.5, 36.4, 35.4, 35.2, 33.8, 31.0, 30.9, 29.5, 28.2, 27.8, 26.8, 26.7, 25.2, 21.4, 17.9, 11.5
  • Mass (m/z)=448.2 [M++18].
  • IR (KBr)=3435, 3039, 2941, 1729, 1448, 1435, 1252, 1022 cm−1.
  • m.p.=122.1-123.9° C. (from EtOAc).
  • [α]D=+56 (c=1% in CHCl3)
  • ELSD Purity: 97.7%: Retention time=14.57 (ZORBAX SB C-18 150×4.6 mm, 5 um, ACN: 0.1% TFA in water (90:10)
    • Example 8 Methyl 3α-acetoxy-5β-chol-9(11), 16-dien-24-oate (1.7b)
  • Figure US20100179337A2-20100715-C00023
  • Ethyl aluminum dichloride (14.2 mL, 25 mmol, 1.8M in toluene) was added to a solution of methyl acrylate (1.89 mL, 20 mmol) in DCM (60 mL) at 0° C. under inert atmosphere. The resulting solution was stirred for 15 min and then compound 1.6a (3 g, 8.7 mmol) was added. After stirring for an additional 20 min at 0° C., the temperature was raised to 25° C. and held there for a further 18 h. At this point the reaction was determined to be complete by TLC, then the mixture was poured into cold (0° C.) water (60 mL). The phases were separated and the aqueous layer was extracted with DCM (60 mL). The organic layers were combined and washed sequentially with water (50 mL) and saturated brine solution (100 mL). It was then dried over anhydrous Na2SO4 (5 g) and filtered. The filtrate was concentrated under vacuum, providing compound 1.7b (2.6 g, 70%).
  • TLC mobile phase: 10%—EtOAc in hexanes.
  • 1H NMR (500 MHz, CDCl3): δ=5.34-5.43 (m, 2H), 4.73-4.75 (m, 1H), 3.73 (s, 3H), 2.15-2.34 (m, 6H), 2.05-2.08 (m, 3H), 2.01 (s, 3H), 1.48-1.99 (m, 9H), 1.24-1.34 (m, 3H), 1.20-1.21 (d, J=5 Hz, 3H), 1.11-1.17 (m, 1H), 1.07 (s, 3H), 0.67 (s, 3H).
  • ELSD Purity: 93.9%, ret. time=4.55, (Water symmetry shield 250×4.6 mm 5μ), ACN: 100%
    • Example 9 Methyl 3α-acetoxy-5β-chol-9(11)-en-24-oate (1.8a)
  • Figure US20100179337A2-20100715-C00024
  • To a solution of compound 1.7a (3 g, 7 mmol) in EtOAc (60 mL) was added 10% Pd/C (300 mg, 10% wt/wt), and the resulting slurry was hydrogenated in a Parr apparatus (70 psi) for 14-16 h. At this point the reaction was determined to be complete by TLC (10% ethyl acetate in hexanes). The mixture was filtered through a small plug of Celite® and the solvent was removed under vacuum, affording compound 1.8a (2.6 g, 86%) as a white solid.
  • 1H NMR (500 MHz, CDCl3): δ=5.31 (s, 1H), 4.73 (m, 1H), 3.66 (s, 3H), 2.37-2.03 (m, 7H), 2.01 (s, 3H), 1.98-1.09 (m, 18H), 1.06 (s, 3H), 0.92-0.91 (d, J=6.0 Hz, 3H), 0.59 (s, 3H).
  • ELSD Purity: 95.9%, ret. time=4.75, (Water symmetry shield 250×4.6 mm 5μ), ACN:Water (60:40)
    • Example 10 Methyl 3α-hydroxy-5β-chol-9(11)-en-12-one-24-oate (1.9a)
  • Figure US20100179337A2-20100715-C00025
  • CrO3 (17.0 g, 170 mmol) was added to a solution of compound 1.8a (17 g, 39.5 mmol) in AcOH (270 mL). The resulting mixture was heated at 50° C. for 24-36 h. Upon complete disappearance of the starting material by TLC, the solvent was evaporated under vacuum and the crude material was dissolved in ethyl acetate (400 mL) and water (200 mL). The two phases were separated and the organic layer was washed twice with water (2×100 mL) and then once with saturated brine solution (100 mL). The organic phase was dried over anhydrous Na2SO4 (40 g) and filtered. The filtrate was concentrated under vacuum and the resulting solid was purified by column chromatography [49 mm (W)×600 mm (L), 60-120 mesh silica, 120 g], eluting with ethyl acetate/hexane (1:5) [10 mL fractions, 3 mL/min elution, monitored by TLC and detected with UV light (254 nm) lamp]. The product-containing fractions were combined and concentrated under vacuum to afford compound 1.9a (8.8 g, 50% yield) as a white solid.
  • TLC: p-anisaldehyde charring, Rf for 1.9a=0.28 and Rf for 18a=0.52.
  • TLC mobile phase: 20%—EtOAc in hexanes.
  • 1H NMR (500 MHz, CDCl3): δ=5.71 (s, 1H), 4.71-4.75 (m, 1H), 3.66 (s, 3H), 2.37-2.42 (m, 3H), 2.02-2.31 (m, 2H), 2.0 (s, 3H), 1.67-1.98 (m, 9H), 1.24-1.56 (m, 9H), 1.19 (s, 3H), 1.01-1.02 (d, J=6.5 Hz, 3H), 0.90 (s, 3H).
  • 13C NMR (500 MHz, CDCl3): δ=204.9, 174.5, 170.4, 163.8, 123.6, 73.7, 53.4, 53.0, 51.3, 47.2, 41.7, 39.8, 37.7, 35.2, 35.0, 33.9, 31.4, 30.5, 29.6, 27.6, 27.3, 26.4, 26.1, 24.1, 21.2, 19.4, 10.6.
  • Mass (m/z)=445.0 [M++1], 462.0 [M++18].
  • IR=3437, 3045, 2946, 2870, 1729, 1680, 1252, 1168, 1020, cm−1.
  • m.p.=137-139° C. (from EtOAc/hexanes mixture).
  • [α]D=+93 (c=1% in CHCl3).
  • ELSD Purity: 94.6%: Retention time=8.68 (Inertsil ODS 3V, 250×4.6 mm, 5 um, ACN:Water (60:40)
    • Example 11 Methyl 3α-acetoxy-5β-cholan-12-one-24-oate (2.0a)
  • Figure US20100179337A2-20100715-C00026
  • 10% Pd/C (900 mg) was added to a solution of compound 1.9a (2.0 g, 4.5 mmol) in EtOAc (150 mL) and the resulting slurry was hydrogenated in a Parr apparatus (50 psi) at 50° C. for 16 h. At this point the reaction was determined to be complete by TLC. The mixture was filtered through a small plug of Celite® and the solvent was removed under vacuum, providing compound 2.0a (1.6 g, 80% yield) as a white solid.
  • TLC: p-anisaldehyde charring, Rf for 2.0=0.36 and Rf for 1.9=0.32.
  • TLC mobile phase: 20%—EtOAc in hexanes.
  • 1H NMR (500 MHz, CDCl3): δ=4.67-4.71 (m, 1H), 3.66 (s, 3H), 2.45-2.50 (t, J=15 Hz, 2H), 2.22-2.40 (m, 1H), 2.01 (s, 3H), 1.69-1.96 (m, 9H), 1.55 (s, 4H), 1.25-1.50 (m, 8H), 1.07-1.19 (m, 2H), 1.01 (s, 6H), 0.84-0.85 (d, J=7.0 Hz, 3H).
  • 13C NMR (125 MHz, CDCl3): δ=214.4, 174.5, 170.4, 73.6, 58.5, 57.4, 51.3, 46.4, 43.9, 41.2, 38.0, 35.6, 35.5, 35.2, 34.8, 32.0, 31.2, 30.4, 27.4, 26.8, 26.2, 25.9, 24.2, 22.6, 21.2, 18.5, 11.6,
  • Mass (m/z)=447.0 [M++1], 464.0 [M++18].
  • IR (KBr)=3445, 2953, 2868, 1731, 1698, 1257, 1029 cm−1.
  • m.p.=142.2-144.4° C. (from EtOAc/hexanes mixture).
  • [α]D=+92 (c=1% in CHCl3).
  • ELSD Purity: 96.6%: Retention time=9.93 (Inertsil ODS 3V, 250×4.6 mm, 5 um, ACN: 0.1% TFA in water (90:10)
    • Example 12 Methyl 3α-acetoxy-12α-hydroxy-5β-cholan-24-oate (2.1a)
  • Figure US20100179337A2-20100715-C00027
  • A THF solution of lithium tri-tert-butoxyaluminum hydride (1 M, 22.4 mL, 22.4 mmol) was added drop wise to a solution of compound 2.0a (2.5 g, 5.6 mmol) in THF (25 mL) at ambient temperature. After stirring for an additional 4-5 h, the reaction was determined to be complete by TLC. The reaction was quenched by adding aqueous HCl (1 M, 10 mL) and the mixture was diluted with EtOAc (30 mL). The phases were separated and the organic phase was washed sequentially with water (15 mL) and saturated brine solution (10 mL). The organic phase was then dried over anhydrous Na2SO4 (3 g) and filtered. The filtrate was concentrated under vacuum and the resulting solid was purified by column chromatography [29 mm (W)×500 mm (L), 60-120 mesh silica, 50 g], eluting with EtOAc/hexane (2:8) [5 mL fractions, monitored by TLC with p-anisaldehyde charring]. The fractions containing the product were combined and concentrated under vacuum to provide compound 2.1a (2.3 g, 91%) as a white solid.
  • TLC: p-anisaldehyde charring, Rf for 2.1a=0.45 and Rf for 2.0a=0.55.
  • TLC mobile phase: 30%—EtOAc in hexanes.
  • 1H NMR (500 MHz, CDCl3): δ=4.68-4.73 (m, 1H), 3.98 (s, 1H), 3.66 (s, 3H), 2.34-2.40 (m, 1H), 2.21-2.26 (m, 1H), 2.01 (s, 3H), 1.75-1.89 (m, 6H), 1.39-1.68 (m, 16H), 1.00-1.38 (m, 3H), 0.96-0.97 (d, J=5.5 Hz, 3H), 0.93 (s, 3H), 0.68 (s, 3H).
  • 13C NMR (125 MHz, CDCl3): δ=174.5, 170.5, 74.1, 72.9, 51.3, 48.1, 47.2, 46.4, 41.7, 35.8, 34.9, 34.7, 34.0, 33.5, 32.0, 30.9, 30.8, 28.6, 27.3, 26.8, 26.3, 25.9, 23.4, 22.9, 21.3, 17.2, 12.6
  • Mass (m/z)=449.0 [M++1], 466.0 [M++18].
  • IR (KBr)=3621, 2938, 2866, 1742, 1730, 1262, 1162, 1041, cm−1.
  • m.p 104.2-107.7° C. (from EtOAc).
  • [α]D=+56 (c=1% in CHCl3).
  • ELSD Purity: 97.0%: Retention time=12.75 (Inertsil ODS 3V, 250×4.6 mm, 5 um, ACN:Water (60:40)
    • Example 13 Deoxycholic Acid (DCA)
  • Figure US20100179337A2-20100715-C00028
  • A solution of LiOH (187 mg, 4.4 mmol) in H2O (2.0 mL) was added to a solution of compound 2.1a (500 mg, 1.11 mmol) in THF (8 mL) and MeOH (8 mL). The resulting mixture was stirred for 3-4 h at 50° C. Upon complete disappearance of the starting material by TLC, the reaction mixture was concentrated under vacuum. A mixture of water (10 mL) and 3 N HCl (1 mL) were combined and cooled to 0 C and then added to the crude product. After stirring for 1 h at 0° C., the precipitated solids were filtered and then washed with water (10 mL) and hexane (20 mL). Drying under vacuum at room temperature provided deoxycholic acid (DCA, 400 mg, 91% yield) as a white solid.
  • TLC: p-anisaldehyde charring, Rf for DCA=0.32 and Rf for 2.1a=0.82.
  • TLC mobile phase: 10%—Methanol in DCM.
  • 1H NMR (500 MHz, DMSO): δ=11.92 (s, 1H), 4.44 (s, 1H), 4.19 (s, 1H), 3.77 (s, 1H), 3.35-3.36 (m, 1H), 2.19-2.21 (m, 1H), 2.08-2.10 (m, 1H), 1.73-1.80 (m, 4H), 1.43-1.63 (m, 6H), 1.15-1.35 (m, 12H), 0.98-1.05 (m, 2H), 0.89-0.90 (d, J=6.0 Hz, 3H), 0.83 (s, 3H), 0.58 (s, 3H).
  • 13C NMR (125 MHz, DMSO): δ=174.8, 71.0, 69.9, 47.4, 46.1, 46.0, 41.6, 36.3, 35.6, 35.1, 34.9, 33.8, 32.9, 30.8, 30.7, 30.2, 28.6, 27.1, 27.0, 26.1, 23.5, 23.0, 16.9, 12.4.
  • Mass (m/z)=393 [M+, +1].
  • IR=3363, 2933, 2863, 1694, 1453, 1372, 1042, cm−1.
  • m.p.=171.4-173.6° C. (from ethanol); 174-176° C. (Alfa Aesar) and 171-174° C. (Aldrich)
  • [α]D=+47 (c=1% in EtOH), +540 (c=2% in ethanol) [Alfa Aesar]
  • ELSD Purity: 99.7%: Retention time=5.25 (Inertsil ODS 3V, 250×4.6 mm, 5 um, ACN: 0.1% TFA in water (90:10).
    • Biological Example 1
  • Primary human adipocytes were incubated with varying concentrations of synthetic sodium deoxycholate synthesized using 9-HAD as starting material or bovine-derived sodium deoxycholate obtained from Sigma as described below.
  • Materials
  • Adipocytes (Zen-Bio cat# SA-1096)
  • 96 well plates (US Scientific cat# cellstar no. 655180)
  • Serum-free RPMI medium (Mediatech cat# 17-105-CV)
  • Sodium deoxycholate (DC) (Sigma cat# D6750)
  • Synthetic Sodium glycodeoxycholate (Kythera)
  • PBS (1×)
  • MTS assay kit (Promega cat# G3580)
  • Adipocytes arrived differentiated and at a density of 13,000 cells per well in a 96 well plate. Two plates were received and each treated with the same samples. Cells were incubated for 24 hours at 37° C. with 5% CO2. A 1% stock solution of each bile acid (synthetic and non-synthetic DCA) were made by dissolving 20 mg into 2 mL media (serum-free). Using the 1% stock solution, the following 11 solutions were prepared by dilution: 0.005%, 0.01%, 0.015%, 0.02%, 0.025%, 0.03%, 0.035%, 0.04%, 0.05%, 0.06%, and 0.1%, as well as 0% (media only).
  • Cells were washed 2× with 150 μL of room temperature 1×PBS (phosphate buffered saline). Media and then PBS were removed from the wells in a 96 well plate by turning the plate upside down and decanting the liquid into a container. After the last PBS wash, 80 μL of sample was added per well. Each concentration of a specific bile acid was added to 8 wells and incubated for 1 hour at 37° C. with 5% CO2. Plates were then removed from incubator and solution was decanted. A 100 μL solution of diluted (40 μL in 1 mL of RPMI) MTS reagent (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt) was added directly to each well. Plates were incubated at 37° C. with 5% CO2 until control (no bile acid) wells changed color to orange-brown and then loaded onto a spectrophotometer that analyzes 96 well plates. Samples were run at 490 nm wavelength setting.
  • Cell viability was assessed using a calorimetric assay (MTS) kit from Promega. The results show a dose-dependent decrease in cell survival upon treatment with either syn-NaDC or Sigma-NaDC (see FIG. 1). Both molecules demonstrated similar cytolytic behavior in this experiment, indicating that synthetic-NaDC and bovine-derived Sigma-NaDC are functionally identical in terms of their ability to kill fat cells.
  • The embodiments and example described above are not intended to limit the invention. It should be understood that numerous modifications and variations are possible in accordance with the principles of the present invention.

Claims (16)

1. A method for preparing deoxycholic acid (DCA) or a pharmaceutically acceptable salt thereof:
Figure US20100179337A2-20100715-C00029
said method comprising
(a) reacting 9α-hydroxyandrost-4-en-3,17-dione 1.0 with H2 under hydrogenation conditions to form compound 1.1
Figure US20100179337A2-20100715-C00030
(b) reacting compound 1.1 with acid to form compound 1.2
Figure US20100179337A2-20100715-C00031
(c) reacting compound 1.2 with a reducing agent to form compound 1.3 or a mixture of 1.3 and 1.4
Figure US20100179337A2-20100715-C00032
(d) reacting compound 1.3 with a two carbon olefination reagent under olefin forming conditions to form compound 1.5
Figure US20100179337A2-20100715-C00033
(e) converting compound 1.5 to a compound of formula 1.6 wherein P is a protecting group
Figure US20100179337A2-20100715-C00034
(f) reacting a compound of formula 1.6 with an alkylpropiolate CHCC(O)OR or an alkyl acrylate CH2═CHC(O)OR wherein R is alkyl in the presence of a Lewis acid to form a compound of formula 1.7 wherein P is a protecting group, R is an alkyl, and the dashed line
Figure US20100179337A2-20100715-P00001
is a single or double bond;
Figure US20100179337A2-20100715-C00035
(g) reacting a compound of formula 1.7 with H2 under hydrogenation conditions to form a compound of formula 1.8 wherein P is a protecting group and R is alkyl
Figure US20100179337A2-20100715-C00036
(h) reacting compound of formula 1.8 with an oxidizing agent to form a compound of formula 1.9 wherein P is a protecting group and R is alkyl
Figure US20100179337A2-20100715-C00037
(i) reacting a compound of formula 1.9 with H2 under hydrogenation conditions to form compound of formula 2.0 wherein P is a protecting group and R is alkyl
Figure US20100179337A2-20100715-C00038
(j) reacting compound of formula 2.0 with a reducing agent to form a compound of formula 2.1 wherein P is a protecting group and R is alkyl
Figure US20100179337A2-20100715-C00039
(k) exposing compound of formula 2.1 to deprotection and hydrolysis conditions to form deoxycholic acid.
2. The method of claim 1 wherein the hydrogenation conditions of part (a) comprises a Pd/C catalyst.
3. The method of claim 1 wherein the acid of part (b) is a mineral acid.
4. The method of claim 3 wherein the mineral acid is H2SO4.
5. The method of claim 1 wherein the reducing agent of part (c) is LiAl(OtBu)3H.
6. The method of claim 1 wherein the two carbon olefination reagent of part (d) is Ph3PCH2CH3 +Br−.
7. The method of claim 1 wherein the protecting group P of compound 1.6-2.1 is —C(O)CH3.
8. The method of claim 1 wherein the Lewis acid of part (f) is EtAlCl2.
9. The method of claim 1 wherein the alkylpropiolate or alkylacrylate is methylpropriolate or methylacrylate.
10. The method of claim 1 wherein the hydrogenation conditions of part (g) comprises a PtO2 catalyst.
11. The method of claim 1 wherein the oxidizing agent of part (h) is CrO3.
12. The method of claim 1 wherein the hydrogenation conditions of part (i) comprises a Pd/C catalyst.
13. The method of claim 1 wherein the reducing agent of part (j) is LiAl(OtBu)3H.
14. The method of claim 1 wherein the deprotection and hydrolysis conditions of part (k) when P is —C(O)CH3 comprises reacting compound 2.1 with an alkali earth hydroxide, alkali earth alkoxide, or a mixture of both.
15. The method of claim 14 wherein the alkali earth alkoxide is LiOH.
16. (canceled)
US12/153,446 2007-06-19 2008-05-16 Preparation of bile acids and intermediates thereof Active 2028-12-21 US7902387B2 (en)

Priority Applications (55)

Application Number Priority Date Filing Date Title
JOP/2018/0077A JOP20180077A1 (en) 2007-06-19 2007-06-19 Synthetic bile acid compositions and methods
KR1020167035728A KR101863131B1 (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
PL11181831T PL2407475T3 (en) 2007-06-19 2008-06-18 synthetic bile acid preparation
PT111818316T PT2407475E (en) 2007-06-19 2008-06-18 Synthetic bile acid preparation
KR1020147035206A KR101598402B1 (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
MYPI20095366A MY160040A (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method and preparation
CA2789109A CA2789109C (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
DK11181831.6T DK2407475T3 (en) 2007-06-19 2008-06-18 Preparation of synthetic bile acid
HUE11181831A HUE025909T2 (en) 2007-06-19 2008-06-18 synthetic bile acid preparation
CA2690841A CA2690841C (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
AU2008265721A AU2008265721B2 (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
SI200831482T SI2407475T1 (en) 2007-06-19 2008-06-18 synthetic bile acid preparation
KR1020097026748A KR20100031512A (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
KR1020137027503A KR20130133881A (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
MX2009013664A MX2009013664A (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation.
KR1020187014779A KR101916024B1 (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
EP08771400A EP2069383A2 (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
JP2010513387A JP2010530876A (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method and preparation thereof
NZ581081A NZ581081A (en) 2007-06-19 2008-06-18 Synthetic deoxycholic acid (dca) or an ester, hydroxamale, or hydroxyamide thereof
PCT/US2008/067391 WO2008157635A2 (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
CR20170070A CR20170070A (en) 2007-06-19 2008-06-18 COMPOSITION, METHOD AND PREPARATION OF SYNTHETIC BILIAR ACID
JOP/2008/0286A JO3172B1 (en) 2007-06-19 2008-06-18 Synthetic bile acid composition,method,and preparation
ES11181831.6T ES2550504T3 (en) 2007-06-19 2008-06-18 Preparation of synthetic bile acid
CN201810072485.3A CN108191940B (en) 2007-06-19 2008-06-18 Synthetic bile acid compositions, methods and formulations
EP15173458.9A EP3002290B1 (en) 2007-06-19 2008-06-18 Synthesis of deoxycholic acid (dca)
EA201000032A EA020806B1 (en) 2007-06-19 2008-06-18 Method for preraring deoxycholic acid (embodiments), deoxycholic acid prepared by said method, pharmaceutical composition containing same, method for removal of fat deposits
TW097122750A TWI503327B (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
KR1020167004581A KR20160025044A (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
CN201610262578.3A CN106146594A (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method and formulation
ES15173458T ES2826429T3 (en) 2007-06-19 2008-06-18 Synthesis of deoxycholic acid (DCA)
CN200880019212A CN101711254A (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
MX2012006571A MX360094B (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation.
CN201610262072.2A CN106083969B (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method and formulation
EP11181831.6A EP2407475B1 (en) 2007-06-19 2008-06-18 synthetic bile acid preparation
BRPI0813140A BRPI0813140C1 (en) 2007-06-19 2008-06-18 method for the preparation of deoxycholic acid (dca) or an ester thereof or a pharmaceutically acceptable salt thereof and intermediate compound
KR1020187031750A KR102061001B1 (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
TW104118229A TWI503396B (en) 2007-06-19 2008-06-18 Synthetic bile acid composition, method, and preparation
ARP080102625A AR067440A1 (en) 2007-06-19 2008-06-19 SYNTHETIC BILIARY ACID, A COMPOSITION THAT INCLUDES IT, A METHOD FOR THEIR PREPARATION, INTERMEDIATE SYNTHESIS COMPOUNDS AND THEIR EMPLOYMENT IN THE ELIMINATION OF BODY FAT DEPOSITS
US12/613,969 US7994351B2 (en) 2008-04-25 2009-11-06 Preparation of bile acids and intermediates thereof
ZA2009/07928A ZA200907928B (en) 2007-06-19 2009-11-11 Synethoc bile acid composition, method, and preparation
IL202203A IL202203B (en) 2007-06-19 2009-11-18 Synthetic bile acid composition and method for preparation of the bile acid
HK12106564.9A HK1165807A1 (en) 2007-06-19 2009-12-10 Synthetic bile acid preparation
CR11174A CR11174A (en) 2007-06-19 2009-12-17 COMPOSITION, METHOD AND PREPARATION OF SYNTHETIC BILIARY ACID
SM201000003T SMP201000003B (en) 2007-06-19 2010-01-13 Composition, method and preparation of synthetic bile acids.
US13/010,727 US8362285B2 (en) 2008-04-25 2011-01-20 Preparation of bile acids and intermediates thereof
US13/115,889 US8367852B2 (en) 2008-04-25 2011-05-25 Preparation of bile acids and intermediates thereof
US13/730,533 US9150607B2 (en) 2008-04-25 2012-12-28 Preparation of bile acids and intermediates thereof
JP2013007521A JP5589102B2 (en) 2007-06-19 2013-01-18 Synthetic bile acid composition, method and preparation thereof
US13/752,175 US20130267721A1 (en) 2008-04-25 2013-01-28 Preparation of bile acids and intermediates thereof
US14/696,204 US10053486B2 (en) 2008-04-25 2015-04-24 Preparation of bile acids and intermediates thereof
HRP20150879TT HRP20150879T1 (en) 2007-06-19 2015-08-18 Synthetic bile acid preparation
CY20151100828T CY1116700T1 (en) 2007-06-19 2015-09-22 PREPARATION OF SYNTHETIC BOLIC ACID
HK16111527.1A HK1223372A1 (en) 2007-06-19 2016-10-04 Synthesis of deoxycholic acid (dca) (dca)
US16/051,409 US10633412B2 (en) 2008-04-25 2018-07-31 Preparation of bile acids and intermediates thereof
US16/856,374 US11008363B2 (en) 2008-04-25 2020-04-23 Preparation of bile acids and intermediates thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0807615.0 2008-04-25
GB0807615A GB2452358C (en) 2008-04-25 2008-04-25 Preparation of bile acids.

Related Child Applications (3)

Application Number Title Priority Date Filing Date
US12/613,969 Continuation US7994351B2 (en) 2008-04-25 2009-11-06 Preparation of bile acids and intermediates thereof
US12/613,969 Division US7994351B2 (en) 2008-04-25 2009-11-06 Preparation of bile acids and intermediates thereof
US13/010,727 Continuation US8362285B2 (en) 2008-04-25 2011-01-20 Preparation of bile acids and intermediates thereof

Publications (3)

Publication Number Publication Date
US20090270642A1 US20090270642A1 (en) 2009-10-29
US20100179337A2 true US20100179337A2 (en) 2010-07-15
US7902387B2 US7902387B2 (en) 2011-03-08

Family

ID=39522602

Family Applications (9)

Application Number Title Priority Date Filing Date
US12/153,446 Active 2028-12-21 US7902387B2 (en) 2007-06-19 2008-05-16 Preparation of bile acids and intermediates thereof
US12/613,969 Active US7994351B2 (en) 2008-04-25 2009-11-06 Preparation of bile acids and intermediates thereof
US13/010,727 Active US8362285B2 (en) 2008-04-25 2011-01-20 Preparation of bile acids and intermediates thereof
US13/115,889 Active US8367852B2 (en) 2008-04-25 2011-05-25 Preparation of bile acids and intermediates thereof
US13/730,533 Active 2028-08-20 US9150607B2 (en) 2008-04-25 2012-12-28 Preparation of bile acids and intermediates thereof
US13/752,175 Abandoned US20130267721A1 (en) 2008-04-25 2013-01-28 Preparation of bile acids and intermediates thereof
US14/696,204 Active US10053486B2 (en) 2008-04-25 2015-04-24 Preparation of bile acids and intermediates thereof
US16/051,409 Active US10633412B2 (en) 2008-04-25 2018-07-31 Preparation of bile acids and intermediates thereof
US16/856,374 Active US11008363B2 (en) 2008-04-25 2020-04-23 Preparation of bile acids and intermediates thereof

Family Applications After (8)

Application Number Title Priority Date Filing Date
US12/613,969 Active US7994351B2 (en) 2008-04-25 2009-11-06 Preparation of bile acids and intermediates thereof
US13/010,727 Active US8362285B2 (en) 2008-04-25 2011-01-20 Preparation of bile acids and intermediates thereof
US13/115,889 Active US8367852B2 (en) 2008-04-25 2011-05-25 Preparation of bile acids and intermediates thereof
US13/730,533 Active 2028-08-20 US9150607B2 (en) 2008-04-25 2012-12-28 Preparation of bile acids and intermediates thereof
US13/752,175 Abandoned US20130267721A1 (en) 2008-04-25 2013-01-28 Preparation of bile acids and intermediates thereof
US14/696,204 Active US10053486B2 (en) 2008-04-25 2015-04-24 Preparation of bile acids and intermediates thereof
US16/051,409 Active US10633412B2 (en) 2008-04-25 2018-07-31 Preparation of bile acids and intermediates thereof
US16/856,374 Active US11008363B2 (en) 2008-04-25 2020-04-23 Preparation of bile acids and intermediates thereof

Country Status (3)

Country Link
US (9) US7902387B2 (en)
GB (1) GB2452358C (en)
JO (1) JOP20180077A1 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013044119A1 (en) * 2011-09-22 2013-03-28 Kythera Biopharmaceuticals, Inc. Compositions and methods related to deoxycholic acid and its polymorphs
US9683007B2 (en) 2009-12-18 2017-06-20 Kythera Biopharmaceuticals, Inc. Methods for the purification of deoxycholic acid

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US20080318870A1 (en) 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
JOP20180077A1 (en) * 2007-06-19 2019-01-30 Kythera Biopharmaceuticals Inc Synthetic bile acid compositions and methods
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
US9127036B2 (en) 2010-08-12 2015-09-08 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
CA2827643C (en) * 2011-02-18 2019-05-07 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US9687455B2 (en) 2014-08-14 2017-06-27 John Daniel Dobak Sodium tetradecyl sulfate formulations for treatment of adipose tissue
EP3236903B1 (en) 2014-12-23 2021-04-21 Intellectual Property Associates, LLC Methods and formulations for transdermal administration
US9351945B1 (en) 2015-02-27 2016-05-31 John Daniel Dobak, III Reduction of adipose tissue
CN106146593B (en) * 2015-04-14 2021-06-01 南京迈诺威医药科技有限公司 Method for preparing deoxycholic acid
KR20180100309A (en) * 2015-11-04 2018-09-10 키쎄라 바이오파마슈티컬즈 인코포레이티드 Methods for the treatment of accumulated fats using deoxycholic acid and its salts

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2509248A (en) * 1947-09-05 1950-05-30 Merck & Co Inc Process for producing delta9, 11-3(alpha)-hydroxy-17-ketoetiocholene
US3065227A (en) * 1961-06-13 1962-11-20 Searle & Co 3alpha, 9alpha-epoxy steroids of the androstane and pregnane series
US3836516A (en) * 1969-08-18 1974-09-17 Hoffmann La Roche Diazo derivatives of antibiotic x-537a
US4322553A (en) * 1981-02-02 1982-03-30 Monsanto Company Process for producing N-(halomethyl)acylamides
US4917827A (en) * 1987-06-12 1990-04-17 Gist-Brocades N.V. Process for the preparation of 9(11)-dehydro steroids
US6114336A (en) * 1996-10-23 2000-09-05 Sanofi Cosmetic composition containing a neuropeptide Y receptor antagonist
US6653492B2 (en) * 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
US20050042539A1 (en) * 2003-08-23 2005-02-24 Korea Advanced Institute Of Science And Technology Novel monomers containing an oxepan-2-one group, photoresist compositions comprising polymers prepared from the monomers, methods for preparing the compositions, and methods for forming photoresist patterns using the compositions
US20050261258A1 (en) * 2004-05-19 2005-11-24 Kolodney Michael S Methods and compositions for the non-surgical removal of fat
US20050267080A1 (en) * 2004-05-19 2005-12-01 Kolodney Michael S Methods and related compositions for reduction of fat
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US20080318870A1 (en) * 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20100145083A1 (en) * 2008-04-25 2010-06-10 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2321598A (en) * 1940-10-07 1943-06-15 George A Breon & Company Inc Preparation of desoxycholic acid
US2615902A (en) 1950-10-24 1952-10-28 Merck & Co Inc Chemical compounds and processes for preparing the same
US2765316A (en) 1953-09-25 1956-10-02 Armour & Co Method for preparing desoxycholic acid
US3891677A (en) 1967-06-06 1975-06-24 Schering Corp 17{60 ,20,20,21-Bismethylenedioxy-4,5-seco-3-pregnyne-5-ones
DE1810033A1 (en) * 1967-12-19 1969-07-10 Richter Gedeon Vegyeszet Process for the production of deoxycholic acid
US4113882A (en) 1974-10-21 1978-09-12 Yamanouchi Pharmaceutical Co., Ltd. Stabilized oral prostaglandin formulation and the process for the preparation thereof
US4226770A (en) 1978-02-10 1980-10-07 Kaiser Emil T Synthesis of steroids
US4310467A (en) 1980-10-22 1982-01-12 Hoffmann-La Roche Inc. Process and intermediates for the synthesis of vitamin D3 metabolites
US4594432A (en) 1983-01-28 1986-06-10 Hoffman-La Roche Inc. Process for the synthesis of 1α,23(S),25-trihydroxycholecalciferol and 1α,23(R),25-trihydroxycholecalciferol
GB8417895D0 (en) 1984-07-13 1984-08-15 Marples B A Pharmaceutical anti-fungal composition
US4866044A (en) 1985-07-09 1989-09-12 Takeda Chemical Industries, Ltd. Solubilized composition of poorly-soluble pharmaceutical product
US4762919A (en) 1986-02-12 1988-08-09 Florida Agricultural And Mechanical University Anti-inflammatory carboxy pregnane derivatives
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
HU208437B (en) 1988-04-08 1993-10-28 Roussel Uclaf Process for producing 9-alpha-hydroxy- -17-methylene-steroides for synthetizing corticosteroides
GB9010087D0 (en) 1990-05-04 1990-06-27 Nat Res Dev Anti-fungal compounds
EP0701444B1 (en) 1993-05-24 2010-04-07 Purdue Pharma Ltd. Methods and compositions for inducing sleep
JP2930181B2 (en) 1995-06-20 1999-08-03 松下電器産業株式会社 Two-dimensional sensor for measuring nerve cell activity and measuring device using the same
WO1998005337A1 (en) 1996-08-01 1998-02-12 Cocensys, Inc. Use of gaba and nmda receptor ligands for the treatment of migraine headache
US6262283B1 (en) 1996-12-06 2001-07-17 Magainin Pharmaceuticals Inc. Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds
FR2763336B1 (en) 1997-05-14 1999-08-06 Lvmh Rech ESTERS OF TOCOPHEROL AND THEIR USES IN COSMETICS AND PHARMACY
DE19834814A1 (en) 1998-08-01 2000-02-03 Beiersdorf Ag Cosmetic and dermatological preparations with an effective content of bile acids, their salts and / or their derivatives
US6417179B1 (en) 1998-10-13 2002-07-09 Craig G. Burkhart Ear wax solution
US6375672B1 (en) 1999-03-22 2002-04-23 Board Of Trustees Of Michigan State University Method for controlling the chemical and heat induced responses of collagenous materials
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
US6573299B1 (en) 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
KR100848344B1 (en) 2000-02-04 2008-07-25 유서홍 Preparation of aqueous clear solution dosage forms with bile acids
JP4323797B2 (en) 2000-07-07 2009-09-02 エイ．ブイ．トップチーブ インスティテュート オブ ペトロケミカル シンセシス Preparation of hydrophilic pressure sensitive adhesives with optimized adhesive properties
AU2002230398A1 (en) 2000-10-06 2002-04-29 Xenoport, Inc. Bile-acid conjugates for providing sustained systemic concentrations of drugs
GB2368197B (en) 2000-10-11 2003-12-03 Channell Ltd Electrical connector and strain relief therefor
ES2271255T3 (en) * 2001-05-02 2007-04-16 Novo Nordisk A/S PREPARATION OF BILIARY ACIDS.
AU2003272072A1 (en) 2002-07-16 2004-02-02 Cadila Healthcare Limited A process to prepare pioglitazone via several intermediates.
US20040118412A1 (en) 2002-12-24 2004-06-24 Piletti-Reyes Gianbattista Alberto Anatomical compression pad system
FR2858413B1 (en) 2003-07-30 2006-11-10 Ungda ANALYTICAL METHOD FOR IDENTIFYING THE NATURAL OR FOSSIL ORIGIN OF TARTARIC ACID BY DETERMINING CARBON 14-COUNTING IN LIQUID SCINTILLATION
US20050089555A1 (en) 2003-10-24 2005-04-28 Aventis Pharma Deutschland Gmbh Medicinal targeted local lipolysis
US20070032464A1 (en) 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
DK1829874T3 (en) 2004-12-22 2014-05-12 Ono Pharmaceutical Co Tricyclic compound and its use
US20060222695A1 (en) * 2005-04-01 2006-10-05 Filiberto Zadini Deoxycholic acid liposome-based dermatological topical preparation
US7758422B2 (en) 2005-04-13 2010-07-20 Microsoft Corporation Hard drive authentication
US20090317376A1 (en) 2005-06-06 2009-12-24 Georgetown University Medical School Compositions And Methods For Lipo Modeling
TWI324062B (en) 2007-04-10 2010-05-01 Univ Kaohsiung Medical Composition for treating cancer cells and synthesis method thereof
MX360094B (en) 2007-06-19 2018-10-19 Kythera Biopharmaceuticals Inc Star Synthetic bile acid composition, method, and preparation.
US8242294B2 (en) 2007-06-19 2012-08-14 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US7683621B1 (en) 2008-09-08 2010-03-23 General Electric Company System and method for tissue point tracking using magnetic resonance imaging
US8318663B2 (en) * 2008-11-26 2012-11-27 Satiogen Pharmaceuticals, Inc. Methods of treating diabetes and/or obesity using an enteroendocrine peptide secretion enhancing agent
US9127036B2 (en) 2010-08-12 2015-09-08 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits

Patent Citations (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2509248A (en) * 1947-09-05 1950-05-30 Merck & Co Inc Process for producing delta9, 11-3(alpha)-hydroxy-17-ketoetiocholene
US3065227A (en) * 1961-06-13 1962-11-20 Searle & Co 3alpha, 9alpha-epoxy steroids of the androstane and pregnane series
US3836516A (en) * 1969-08-18 1974-09-17 Hoffmann La Roche Diazo derivatives of antibiotic x-537a
US4322553A (en) * 1981-02-02 1982-03-30 Monsanto Company Process for producing N-(halomethyl)acylamides
US4917827A (en) * 1987-06-12 1990-04-17 Gist-Brocades N.V. Process for the preparation of 9(11)-dehydro steroids
US6114336A (en) * 1996-10-23 2000-09-05 Sanofi Cosmetic composition containing a neuropeptide Y receptor antagonist
US6313128B1 (en) * 1996-10-23 2001-11-06 Sanofi-Synthelabo Cosmetic composition containing a neuropeptide Y receptor antagonist
US6653492B2 (en) * 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
US20050042539A1 (en) * 2003-08-23 2005-02-24 Korea Advanced Institute Of Science And Technology Novel monomers containing an oxepan-2-one group, photoresist compositions comprising polymers prepared from the monomers, methods for preparing the compositions, and methods for forming photoresist patterns using the compositions
US6936402B2 (en) * 2003-08-23 2005-08-30 Korea Advanced Institute Science & Technology Monomers containing an oxepan-2-one group, photoresist compositions comprising polymers prepared from the monomers, methods for preparing the compositions, and methods for forming photoresist patterns using the compositions
US20050261258A1 (en) * 2004-05-19 2005-11-24 Kolodney Michael S Methods and compositions for the non-surgical removal of fat
US20050267080A1 (en) * 2004-05-19 2005-12-01 Kolodney Michael S Methods and related compositions for reduction of fat
US20060127468A1 (en) * 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
US20060154906A1 (en) * 2004-05-19 2006-07-13 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods and related compositions for the non-surgical removal of fat
US20080318870A1 (en) * 2007-06-19 2008-12-25 Kythera Biopharmaceuticals, Inc. Synthetic bile acid compositions and methods
US20080319221A1 (en) * 2007-06-22 2008-12-25 Bernd Junker Esters of Pentahydroxyhexylcarbamoyl Alkanoic Acids
US20100145083A1 (en) * 2008-04-25 2010-06-10 Kythera Biopharmaceuticals, Inc. Preparation of bile acids and intermediates thereof

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9683007B2 (en) 2009-12-18 2017-06-20 Kythera Biopharmaceuticals, Inc. Methods for the purification of deoxycholic acid
US10005813B2 (en) 2009-12-18 2018-06-26 Kythera Biopharmaceuticals, Inc. Methods for the purification of deoxycholic acid
US10472384B2 (en) 2009-12-18 2019-11-12 Allergan Sales, Llc Methods for the purification of deoxycholic acid
US10981946B2 (en) 2009-12-18 2021-04-20 Allergan Sales, Llc Methods for the purification of deoxycholic acid
WO2013044119A1 (en) * 2011-09-22 2013-03-28 Kythera Biopharmaceuticals, Inc. Compositions and methods related to deoxycholic acid and its polymorphs

Also Published As

Publication number Publication date
US7994351B2 (en) 2011-08-09
JOP20180077A1 (en) 2019-01-30
US7902387B2 (en) 2011-03-08
US11008363B2 (en) 2021-05-18
US10053486B2 (en) 2018-08-21
GB2452358B (en) 2009-12-09
US20190048037A1 (en) 2019-02-14
US8367852B2 (en) 2013-02-05
US20100145083A1 (en) 2010-06-10
US20090270642A1 (en) 2009-10-29
US20130190517A1 (en) 2013-07-25
US20130267721A1 (en) 2013-10-10
US20150299245A1 (en) 2015-10-22
US20110152552A1 (en) 2011-06-23
US9150607B2 (en) 2015-10-06
GB2452358A (en) 2009-03-04
GB0807615D0 (en) 2008-06-04
US20200317716A1 (en) 2020-10-08
GB2452358C (en) 2010-12-29
US20110224448A1 (en) 2011-09-15
US8362285B2 (en) 2013-01-29
US10633412B2 (en) 2020-04-28

Similar Documents

Publication Publication Date Title
US11008363B2 (en) Preparation of bile acids and intermediates thereof
US10981946B2 (en) Methods for the purification of deoxycholic acid
EP2407475B1 (en) synthetic bile acid preparation
US9949986B2 (en) Synthetic bile acid compositions and methods
EP3138850B1 (en) Compositions containing deoxycholic acid and 10% deionized water in ethanol, directed to the purification of deoxycholic acid
GB2460350A (en) Preparation of bile acids and intermediates thereof

Legal Events

Date Code Title Description
AS Assignment

Owner name: KYTHERA BIOPHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRASAD, ACHAMPETA RATHAN;SWARINGEN, ROY A, JR.;REID, JOHN GREGORY;AND OTHERS;REEL/FRAME:021444/0894;SIGNING DATES FROM 20080703 TO 20080716

Owner name: KYTHERA BIOPHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PRASAD, ACHAMPETA RATHAN;SWARINGEN, ROY A, JR.;REID, JOHN GREGORY;AND OTHERS;SIGNING DATES FROM 20080703 TO 20080716;REEL/FRAME:021444/0894

AS Assignment

Owner name: KYTHERA BIOPHARMACEUTICALS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SAHOO, AKHILA KUMAR;REEL/FRAME:022010/0078

Effective date: 20081106

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8

AS Assignment

Owner name: KYTHERA BIOPHARMACEUTICALS, LLC, DELAWARE

Free format text: CHANGE OF NAME;ASSIGNOR:KYTHERA BIOPHARMACEUTICALS, INC.;REEL/FRAME:050672/0675

Effective date: 20181231

AS Assignment

Owner name: ALLERGAN SALES, LLC, NEW JERSEY

Free format text: MERGER AND CHANGE OF NAME;ASSIGNORS:KYTHERA BIOPHARMACEUTICALS, LLC;ALLERGAN SALES, LLC;REEL/FRAME:050834/0182

Effective date: 20190328

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 12TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1553); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 12